Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 1997

View Archived Issues

Company Profile: Synaptic

Merck & Co. reports new product candidate and pipeline overview

Abelcet continues to demonstrate effectiveness

New data on PDL's SMART M195 antibody reported

Alfacell: Q1 1998 highlights

BTG: Six-month 1997 highlights

Immune Response recommended to continue Remune phase III trial

LXR discovers new apoptosis-related proteins and genes

Tokyo Tanabe moves new oxytocin antagonist to clinic

Daiichi files for approval of ebselen

Kyowa Hakko prepares new, water-soluble indole for osteoporosis

Hokuriku describes new calcium agonist derived from intracellular calcium antagonist

Diphosphonate antiarthritic agent developed at Toray

Site-directed, sustained-release delivery system for estradiol in development at Fujisawa

Preclinical profile of optically active triazole antifungal agent presented by Takeda

TheraTech and P&G to codevelop hormone replacement patches

Effects of BO-653 and related compounds on various active oxygen species

Alza and Warner-Lambert sign distribution agreement for nasal decongestant OTC

Phase I trial of oral TBC-11251 successfully completed

EU approves ciclosporin bulk substance

Ligand reports positive results from U.S. pivotal phase III trial of Panretin Gel

Alferon N Injection completes phase III in HIV

MedImmune and SKB establish worldwide alliance for HPV vaccines

Cel-Sci expands Multikine trial

First FDA approval for humanized MAb: Zenapax for renal transplant patients

Genzyme Transgenics' idiotypic vaccines show promise in clinical trials

FDA approves URSO for PBC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...